CN107033233A - 非糖基化蛋白质的纯化 - Google Patents

非糖基化蛋白质的纯化 Download PDF

Info

Publication number
CN107033233A
CN107033233A CN201710044891.4A CN201710044891A CN107033233A CN 107033233 A CN107033233 A CN 107033233A CN 201710044891 A CN201710044891 A CN 201710044891A CN 107033233 A CN107033233 A CN 107033233A
Authority
CN
China
Prior art keywords
chromatography
exchange chromatography
ifn
chromatographic
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710044891.4A
Other languages
English (en)
Chinese (zh)
Inventor
R·法尔肯施泰因
B·魏丹兹
C·吉赛尔
S·格赖塔纳
A·格罗斯曼
F·赫西
B·克雷默
M·蓬皮阿蒂
A·肖布马尔
N·菲尔勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN107033233A publication Critical patent/CN107033233A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201710044891.4A 2008-01-18 2009-01-15 非糖基化蛋白质的纯化 Pending CN107033233A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08000884 2008-01-18
EP08000884.0 2008-01-18
CN2009801023313A CN101918430A (zh) 2008-01-18 2009-01-15 非糖基化蛋白质的纯化

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2009801023313A Division CN101918430A (zh) 2008-01-18 2009-01-15 非糖基化蛋白质的纯化

Publications (1)

Publication Number Publication Date
CN107033233A true CN107033233A (zh) 2017-08-11

Family

ID=39810157

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710044891.4A Pending CN107033233A (zh) 2008-01-18 2009-01-15 非糖基化蛋白质的纯化
CN2009801023313A Pending CN101918430A (zh) 2008-01-18 2009-01-15 非糖基化蛋白质的纯化

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2009801023313A Pending CN101918430A (zh) 2008-01-18 2009-01-15 非糖基化蛋白质的纯化

Country Status (9)

Country Link
US (3) US20110034672A1 (https=)
EP (1) EP2245044A2 (https=)
JP (2) JP5944101B2 (https=)
KR (1) KR20100103595A (https=)
CN (2) CN107033233A (https=)
AU (1) AU2009204998B2 (https=)
CA (1) CA2711375C (https=)
IL (1) IL206158A (https=)
WO (1) WO2009090056A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009090056A2 (en) * 2008-01-18 2009-07-23 F. Hoffmann-La Roche Ag Purification of not-glycosylated polypeptides
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
CN102219848B (zh) * 2011-05-25 2014-01-22 浙江海正药业股份有限公司 重组人干扰素β-1a的纯化方法
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
CN104710527B (zh) * 2015-02-28 2018-08-24 苏州金盟生物技术有限公司 一种生物制品的内毒素去除方法
KR102775456B1 (ko) * 2015-11-09 2025-02-28 바이오로지칼 이 리미티드 생물학적 활성 재조합 캐리어 단백질을 회수하기 위한 산업적 확장성이 있는 방법
TW202128264A (zh) * 2019-09-25 2021-08-01 瑞士商赫孚孟拉羅股份公司 使用經預測之溶離緩衝鹽濃度的陽離子層析法
US20220227805A1 (en) * 2020-12-23 2022-07-21 Jazz Pharmaceuticals Ireland Ltd. Methods of purifying charge-shielded fusion proteins
CN113480632B (zh) * 2021-07-30 2023-02-03 宁波人健药业集团股份有限公司 一种在CHO细胞中表达的重组蛋白rhCG纯化工艺
TW202403043A (zh) 2022-03-18 2024-01-16 美商健臻公司 重組人類酸性鞘磷脂酶醫藥組合物及方法
CN117024561B (zh) * 2023-10-10 2024-02-20 哈药集团生物工程有限公司 一种聚乙二醇修饰干扰素的纯化方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0043980A2 (en) * 1980-07-01 1982-01-20 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Mature human leukocyte interferon A, process for its microbial preparation, intermediates therefor and compositions containing it.
CN1099799A (zh) * 1993-05-26 1995-03-08 贝林格尔-英格海姆国际有限公司 制备和纯化α-干扰素的方法
DE4329756A1 (de) * 1993-09-03 1995-03-09 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von alpha-Interferon
EP0809996A2 (en) * 1996-05-31 1997-12-03 F. Hoffmann-La Roche Ag Interferon conjugates
CN1548525A (zh) * 2002-04-16 2004-11-24 海南海梁生物高科技有限公司 酵母重组株及IFNα-la干扰素的纯化方法
WO2005017174A2 (en) * 2003-08-13 2005-02-24 Sandoz Ag Process for the purification of recombinant polypeptides
CN1916024A (zh) * 2005-08-17 2007-02-21 海南国栋药物研究所有限公司 高比活人α－2b干扰素突变体序列、酵母表达质粒的构建及菌株筛选和纯化方法
WO2007041713A1 (en) * 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29
CN103864915A (zh) * 2012-12-07 2014-06-18 天津华立达生物工程有限公司 纯化重组人干扰素α2b的方法和试剂盒
CN104356223A (zh) * 2014-11-26 2015-02-18 安徽安科生物工程（集团）股份有限公司 高纯度重组人干扰素α2b的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696238A (en) * 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
DK0679718T3 (da) 1994-04-09 2001-10-22 Hoffmann La Roche Fremgangsmåde til fremstilling af alfa-interferon
KR100443890B1 (ko) 2001-04-11 2004-08-09 한미약품 주식회사 재조합 대장균으로부터 인간 성장 호르몬의 정제 방법
CA2478925C (en) * 2002-04-26 2016-06-07 Robert Lee Fahrner Non-affinity purification of proteins
RS50516B (sr) 2003-11-05 2010-05-07 Ares Trading S.A. Prečišćavanje il-18 vezujućeg proteina
CA2544333A1 (en) 2003-12-22 2005-07-14 Ares Trading S.A. Method for purifying fsh
SE0400886D0 (sv) * 2004-04-02 2004-04-02 Amersham Biosciences Ab Process of purification
AU2005245918A1 (en) * 2004-05-19 2005-12-01 F. Hoffmann-La Roche Ag Interferon-alpha polypeptides and conjugates
WO2006101441A2 (en) 2005-03-24 2006-09-28 Straumann Holding Ag Method for protein purification comprising heat incubation in acetic acidic solution
WO2007016250A1 (en) 2005-07-28 2007-02-08 Genvec, Inc. Method of purifying protein
WO2007075283A2 (en) 2005-12-06 2007-07-05 Amgen Inc. Polishing steps used in multi-step protein purification processes
WO2009090056A2 (en) * 2008-01-18 2009-07-23 F. Hoffmann-La Roche Ag Purification of not-glycosylated polypeptides

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0043980A2 (en) * 1980-07-01 1982-01-20 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Mature human leukocyte interferon A, process for its microbial preparation, intermediates therefor and compositions containing it.
CN1099799A (zh) * 1993-05-26 1995-03-08 贝林格尔-英格海姆国际有限公司 制备和纯化α-干扰素的方法
US5710027A (en) * 1993-05-26 1998-01-20 Boehringer Ingelheim International Gmbh Process and vector for expressing alpha-interferon in E. coli
DE4329756A1 (de) * 1993-09-03 1995-03-09 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von alpha-Interferon
EP0809996A2 (en) * 1996-05-31 1997-12-03 F. Hoffmann-La Roche Ag Interferon conjugates
CN1548525A (zh) * 2002-04-16 2004-11-24 海南海梁生物高科技有限公司 酵母重组株及IFNα-la干扰素的纯化方法
WO2005017174A2 (en) * 2003-08-13 2005-02-24 Sandoz Ag Process for the purification of recombinant polypeptides
CN1916024A (zh) * 2005-08-17 2007-02-21 海南国栋药物研究所有限公司 高比活人α－2b干扰素突变体序列、酵母表达质粒的构建及菌株筛选和纯化方法
WO2007041713A1 (en) * 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29
CN103864915A (zh) * 2012-12-07 2014-06-18 天津华立达生物工程有限公司 纯化重组人干扰素α2b的方法和试剂盒
CN104356223A (zh) * 2014-11-26 2015-02-18 安徽安科生物工程（集团）股份有限公司 高纯度重组人干扰素α2b的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OLIVER CROMWELL ET AL.: "Transition of recombinant allergens from bench to clinical application", 《METHODS》 *

Also Published As

Publication number Publication date
EP2245044A2 (en) 2010-11-03
CA2711375C (en) 2019-04-16
CA2711375A1 (en) 2009-07-23
AU2009204998A1 (en) 2009-07-23
CN101918430A (zh) 2010-12-15
US20130190478A1 (en) 2013-07-25
WO2009090056A2 (en) 2009-07-23
JP2014210797A (ja) 2014-11-13
US20110034672A1 (en) 2011-02-10
IL206158A0 (en) 2010-12-30
KR20100103595A (ko) 2010-09-27
WO2009090056A3 (en) 2010-01-21
JP2011509963A (ja) 2011-03-31
AU2009204998B2 (en) 2014-03-27
US9481706B2 (en) 2016-11-01
US20140220633A1 (en) 2014-08-07
IL206158A (en) 2016-09-29
JP5944101B2 (ja) 2016-07-05

Similar Documents

Publication Publication Date Title
CN107033233A (zh) 非糖基化蛋白质的纯化
CN102712673B (zh) 用于纯化含fc的蛋白的色谱方法
TWI395619B (zh) 層析方法
DK3040346T3 (en) PROCEDURE FOR CLEANING THE GRANULOCYT COLONY STIMULATING FACTOR, G-CSF
CN101889023A (zh) Peg化的多肽的纯化
KR20070072510A (ko) 항체 정제를 위한 친화도- 및 이온 교환- 크로마토그래피
US20220017570A1 (en) Method for purifying pegylated protein
KR20200104381A (ko) 페길화 단백질 조성물의 제공 방법
CN103703015B (zh) 阳离子和阴离子交换层析法
JP5635682B2 (ja) 疎水性相互作用クロマトグラフィー法
US20250215050A1 (en) Compositions and methods for purifying biological fluids
EP4263568B1 (en) Methods for the purification of refolded fc-peptide fusion protein
HK1193617A (en) Cation and anion exchange chromatography method
HK40102561B (en) Methods for the purification of refolded fc-peptide fusion protein
HK40102561A (en) Methods for the purification of refolded fc-peptide fusion protein
HK1181458A (en) Hydrophobic interaction chromatography method
HK1193617B (zh) 阳离子和阴离子交换层析法
Driebergen Chromatographic Techniques for

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170811

WD01 Invention patent application deemed withdrawn after publication